Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the...
Viracta (VIRX) is a clinical stage biotech firm focused on the treatment of Epstein-Barr related cancers which is one of the most common virus infections found in humans. Had a good run last week, and one of those stocks that can really move with some good news. Might be worth a look.
$VIRX Target 20.39 for 49.27%
Or next add level is at 6.93
Ok this one goes out past my projection date... but try me... 50% here. GL
I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly...
VIRX is sitting in the exact same situation as GME was just a short while ago, with the difference being that VIRX only has a 100,000 share float. This stock could go up to the thousands, or tens of thousands per share, with only a little effort. Oh yeah, the shorts only have one day left to cover. Now is the time to get in.
Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement
Shares of Viracta to commence trading on the Nasdaq Global Select Market on February 25, 2021 under ticker symbol 'VIRX'
Cash and cash equivalents of over $120 million as of merger close
Registration trial for the treatment of relapsed/refractory...
